These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 37597159)

  • 1. Six-Month Persistence and Multi-domain Effectiveness of Guselkumab in Adults with Psoriatic Arthritis: Real-World Data from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry.
    Mease PJ; Ogdie A; Tesser J; Shiff NJ; Lin I; Chakravarty SD; Kelleman M; Dodge R; McLean RR; Broadwell A; Kavanaugh A; Merola JF
    Rheumatol Ther; 2023 Dec; 10(6):1479-1501. PubMed ID: 37597159
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improvements in Patient-Reported Outcomes Through Six Months of Guselkumab Treatment in Patients With Active Psoriatic Arthritis: Real-World Data From the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry.
    Mease PJ; Ogdie A; Tesser J; Shiff NJ; Zhao RS; Chakravarty SD; Kelleman M; Dodge R; McLean RR; Broadwell A; Kavanaugh A; Merola JF
    ACR Open Rheumatol; 2024 May; 6(5):304-311. PubMed ID: 38417434
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical Characteristics of Registry Participants with Psoriatic Arthritis Initiating Guselkumab: An Analysis from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry.
    Mease PJ; Ogdie A; Chakravarty SD; Shiff NJ; Lin I; McLean RR; Malley W; Spitzer RL; Kavanaugh A; Merola JF
    Drugs Real World Outcomes; 2022 Dec; 9(4):617-628. PubMed ID: 36243860
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness of Tofacitinib in Patients Initiating Therapy for Psoriatic Arthritis: Results from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry.
    Mease PJ; Young P; Fallon L; Mundayat R; Dina O; Blachley T; Middaugh N; Ogdie A
    Rheumatol Ther; 2024 Apr; 11(2):313-329. PubMed ID: 38252211
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of guselkumab in biologic-naïve patients with active axial psoriatic arthritis: study protocol for STAR, a phase 4, randomized, double-blinded, placebo-controlled trial.
    Gladman DD; Mease PJ; Bird P; Soriano ER; Chakravarty SD; Shawi M; Xu S; Quinn ST; Gong C; Leibowitz E; Poddubnyy D; Tam LS; Helliwell PS; Kavanaugh A; Deodhar A; Østergaard M; Baraliakos X
    Trials; 2022 Sep; 23(1):743. PubMed ID: 36064592
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Demographics, Disease Characteristics, and Patient-Reported Outcomes Among Patients with Psoriasis Who Initiated Guselkumab in CorEvitas' Psoriasis Registry.
    Walsh JA; Callis Duffin K; Van Voorhees AS; Chakravarty SD; Fitzgerald T; Teeple A; Rowland K; Uy J; McLean RR; Malley W; Cronin A; Merola JF
    Dermatol Ther (Heidelb); 2022 Jan; 12(1):97-119. PubMed ID: 34822121
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PsABIOnd Study and eDaily Substudy Design: Long-Term Effectiveness and Safety of Guselkumab and IL-17 Inhibitors in Routine Clinical Practice in Patients with Psoriatic Arthritis.
    Siebert S; Behrens F; Lubrano E; Martin N; Sharaf M; Contré C; Theander E; Queiro R; Zimmermann M; Gossec L
    Rheumatol Ther; 2023 Apr; 10(2):489-505. PubMed ID: 36585602
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-World Effectiveness of 9-12 Months of Guselkumab Therapy among Patients with Moderate-to-Severe Plaque Psoriasis in the CorEvitas Psoriasis Registry.
    Armstrong AW; Fitzgerald T; McLean RR; Teeple A; Uy JP; Olurinde M; Rowland K; Guo L; Shan Y; Callis Duffin K
    Dermatol Ther (Heidelb); 2023 Feb; 13(2):629-640. PubMed ID: 36585606
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-Term Safety of Guselkumab in Patients with Psoriatic Disease: An Integrated Analysis of Eleven Phase II/III Clinical Studies in Psoriasis and Psoriatic Arthritis.
    Strober B; Coates LC; Lebwohl MG; Deodhar A; Leibowitz E; Rowland K; Kollmeier AP; Miller M; Wang Y; Li S; Chakravarty SD; Chan D; Shawi M; Yang YW; Thaҫi D; Rahman P
    Drug Saf; 2024 Jan; 47(1):39-57. PubMed ID: 37906417
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of guselkumab on inhibiting radiographic progression in patients with active psoriatic arthritis: study protocol for APEX, a Phase 3b, multicenter, randomized, double-blind, placebo-controlled trial.
    Ritchlin CT; Coates LC; Mease PJ; van der Heijde D; Song J; Jiang Y; Shawi M; Kollmeier AP; Rahman P
    Trials; 2023 Jan; 24(1):22. PubMed ID: 36627711
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sustained and improved guselkumab response in patients with active psoriatic arthritis regardless of baseline demographic and disease characteristics: pooled results through week 52 of two phase III, randomised, placebo-controlled studies.
    Ritchlin CT; Mease PJ; Boehncke WH; Tesser J; Schiopu E; Chakravarty SD; Kollmeier AP; Xu XL; Shawi M; Jiang Y; Sheng S; Wang Y; Xu S; Merola JF; McInnes IB; Deodhar A
    RMD Open; 2022 Mar; 8(1):. PubMed ID: 35296534
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Guselkumab provides durable improvement across psoriatic arthritis disease domains: post hoc analysis of a phase 3, randomised, double-blind, placebo-controlled study.
    Coates LC; Gossec L; Zimmermann M; Shawi M; Rampakakis E; Shiff NJ; Kollmeier AP; Xu XL; Nash P; Mease PJ; Helliwell PS
    RMD Open; 2024 Mar; 10(1):. PubMed ID: 38531621
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Effect of Guselkumab on Work Productivity in Biologic-Naïve Patients with Active Psoriatic Arthritis Through Week 52 of the Phase 3, Randomized, Placebo-Controlled DISCOVER-2 Trial.
    Curtis JR; McInnes IB; Rahman P; Gladman DD; Peterson S; Agarwal P; Yang F; Kollmeier AP; Hsia EC; Shiff NJ; Zhou B; Han C; Shawi M; Tillett W; Mease PJ
    Adv Ther; 2022 Oct; 39(10):4613-4631. PubMed ID: 35947349
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Guselkumab effectiveness and survival in patients with psoriasis and psoriatic arthritis: Multicenter analysis in daily clinical practice by the Spanish Psoriasis Group.
    Rocamora V; Crespi L; Ferran M; Llamas-Velasco M; Del Alcázar E; Carrascosa JM; Beltran E; Urruticoechea-Arana A; Estebaranz JLL; Vidal D; Riera J; Rodríguez L; Armesto S; Fernández JM; Aparicio G; Pérez S; Porcar S; Montesinos E; Gallardo F
    Dermatol Ther; 2022 Nov; 35(11):e15865. PubMed ID: 36175141
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Effect of Guselkumab on General Health State in Biologic-Naïve Patients with Active Psoriatic Arthritis Through Week 52 of the Phase 3, Randomized, Placebo-Controlled DISCOVER-2 Trial.
    Curtis JR; McInnes IB; Rahman P; Gladman DD; Yang F; Peterson S; Agarwal P; Kollmeier AP; Hsia EC; Han C; Shiff NJ; Shawi M; Tillett W; Mease PJ
    Adv Ther; 2022 Oct; 39(10):4632-4644. PubMed ID: 35947348
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness of Guselkumab Therapy among Patients with Plaque Psoriasis with Baseline IGA Score ≥ 2 in the CorEvitas Psoriasis Registry.
    Armstrong AW; Fitzgerald T; McLean RR; Teeple A; Uy JP; Olurinde M; Rowland K; Guo L; Shan Y; Callis Duffin K
    Dermatol Ther (Heidelb); 2023 Feb; 13(2):487-504. PubMed ID: 36484917
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of Guselkumab in Treating Nails, Scalp, Hands, and Feet in Patients with Psoriasis and Self-reported Psoriatic Arthritis.
    Orbai AM; Chakravarty SD; You Y; Shawi M; Yang YW; Merola JF
    Dermatol Ther (Heidelb); 2023 Nov; 13(11):2859-2868. PubMed ID: 37713133
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Earlier clinical response predicts low rates of radiographic progression in biologic-naïve patients with active psoriatic arthritis receiving guselkumab treatment.
    Mease PJ; Gottlieb AB; Ogdie A; McInnes IB; Chakravarty SD; Rampakakis E; Kollmeier A; Xu XL; Shawi M; Lavie F; Kishimoto M; Rahman P
    Clin Rheumatol; 2024 Jan; 43(1):241-249. PubMed ID: 37787903
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Guselkumab demonstrated an independent treatment effect in reducing fatigue after adjustment for clinical response-results from two phase 3 clinical trials of 1120 patients with active psoriatic arthritis.
    Rahman P; Mease PJ; Helliwell PS; Deodhar A; Gossec L; Kavanaugh A; Kollmeier AP; Hsia EC; Zhou B; Lin X; Shawi M; Karyekar CS; Han C
    Arthritis Res Ther; 2021 Jul; 23(1):190. PubMed ID: 34261541
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Composite Measures of Disease Activity in Psoriatic Arthritis: Comparative Instrument Performance Based on the Efficacy of Guselkumab in an Interventional Phase II Trial.
    Helliwell PS; Deodhar A; Gottlieb AB; Boehncke WH; Xu XL; Xu S; Wang Y; Hsia EC; Gladman DD; Ritchlin CT
    Arthritis Care Res (Hoboken); 2020 Nov; 72(11):1579-1588. PubMed ID: 31421033
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.